[SCHEDULE 13G] Tvardi Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Sporos Bioventures LLC reported direct beneficial ownership of 837,636 shares of Tvardi Therapeutics common stock, equal to 8.95% of the outstanding class. The filer discloses sole voting power and sole dispositive power over these shares, and reports no shared voting or dispositive arrangements.

This Schedule 13G statement records a material, reportable passive stake above the 5% threshold and provides investors with clear disclosure of concentrated ownership and voting control of a meaningful minority position in TVRD.

Positive

• Material ownership disclosed: Sporos Bioventures reports 837,636 shares (8.95%) of TVRD
• Sole voting and dispositive power: filer controls voting and disposition of the reported shares
• Regulatory transparency: timely Schedule 13G disclosure provides investors with clear ownership information

Negative

• Concentrated ownership: an 8.95% stake represents a meaningful minority position that could influence shareholder votes
• Single-holder concentration: absence of shared or group reporting places significant visibility on one holder

Insights

Financial Analyst

TL;DR: Sporos Bioventures holds 837,636 TVRD shares (8.95%) with sole voting/dispositive power — a material, reportable stake.

The filing shows a direct beneficial holding of 837,636 shares, representing 8.95% of the class, with sole authority to vote and dispose of those shares and no shared control disclosed. For investors, this is a clear, material ownership disclosure above the 5% reporting threshold that can affect shareholder vote dynamics. The statement does not identify any group affiliation or shared control.

Corporate Governance Expert

TL;DR: Sole voting/dispositive power over an 8.95% stake grants the holder meaningful voting influence; no group members are reported.

The report documents exclusive voting and dispositive authority for Sporos Bioventures over a near 9% stake in Tvardi Therapeutics, which is large enough to be material in corporate governance contexts. The filing is a Schedule 13G disclosure and lists no shared or group control, highlighting concentrated ownership that could matter at shareholder meetings or on contested votes, although the filing itself does not signal intent to act in concert or seek control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tvardi Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

140755208

(CUSIP Number)

04/15/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 140755208

1

Names of Reporting Persons

Sporos Bioventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 837,636.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 837,636.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

837,636.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.95 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tvardi Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 3 Sugar Creek Ctr Blvd, Ste 525, Sugar Land, Texas, 77478
Item 2.
(a)	Name of person filing: Sporos Bioventures LLC
(b)	Address or principal business office or, if none, residence: 3139 West Holcombe Blvd, Houston, Texas, 77025
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 140755208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Sporos Bioventures LLC directly owns 837,636 shares of Common Stock
(b)	Percent of class: 8.95 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 837,636
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 837,636
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sporos Bioventures LLC

Signature:	/s/ Stephen Rubino
Name/Title:	Stephen Rubino, Chief Executive Officer
Date:	08/08/2025

FAQ

Who filed the Schedule 13G for TVRD?

Sporos Bioventures LLC filed the Schedule 13G reporting its beneficial ownership.

How many Tvardi Therapeutics (TVRD) shares does Sporos Bioventures own?

837,636 shares of common stock are reported as directly beneficially owned.

What percentage of TVRD does the reported stake represent?

The reported holding represents 8.95% of the outstanding class of common stock.

Does the filer have voting or dispositive power over the shares?

Yes. The filer reports sole voting power and sole dispositive power over the 837,636 shares; shared power is reported as 0.

What form was filed to disclose this ownership?

The ownership was disclosed on a Schedule 13G statement for Tvardi Therapeutics, Inc.

Is the filer part of a group or reporting shared control?

No. The filing indicates no group affiliation and reports no shared voting or dispositive power.

Where are Tvardi Therapeutics' principal executive offices listed in the filing?

The filing lists the issuer's principal executive offices at 3 Sugar Creek Ctr Blvd, Ste 525, Sugar Land, Texas 77478.